Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.
Product Information
Catalog Num
AT0622
Molecular Weight
143060
CAS Number
912628-39-8
Isotype
Human IgG1 lambda1, Isotype Control
Synonyms
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
